

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>Patel Sanj K</u>			2. Issuer Name and Ticker or Trading Symbol <u>Kiniksa Pharmaceuticals International, plc</u> [ <u>KNSA</u> ]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <b>CHAIRMAN &amp; CEO</b>		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>05/23/2025</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
23 OLD BOND STREET, THIRD FLOOR			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street) <u>LONDON X0 W1S 4PZ</u>								
(City) (State) (Zip)								

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Class A Ordinary Share	05/23/2025		M <sup>(1)</sup>		4,837	A	\$1.59	101,511	D	
Class A Ordinary Share	05/23/2025		S <sup>(1)</sup>		4,837	D	\$27 <sup>(2)</sup>	96,674	D	
Class A Ordinary Share	05/27/2025		M <sup>(1)</sup>		19,317	A	\$1.59	115,991	D	
Class A Ordinary Share	05/27/2025		S <sup>(1)</sup>		19,317	D	\$27.01 <sup>(3)</sup>	96,674	D	
Class A Ordinary Share	05/28/2025		M <sup>(1)</sup>		62,116	A	\$1.59	158,790	D	
Class A Ordinary Share	05/28/2025		S <sup>(1)</sup>		62,116	D	\$27.33 <sup>(4)</sup>	96,674	D	
Class A Ordinary Share								109,795	I	Held by The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V		Date Exercisable	Expiration Date						Amount or Number of Shares
Share Option	\$1.59	05/23/2025		M <sup>(1)</sup>		4,837	(5)	12/15/2025	Class A Ordinary Share	4,837	\$0	81,433	D	
Share Option	\$1.59	05/27/2025		M <sup>(1)</sup>		19,317	(5)	12/15/2025	Class A Ordinary Share	19,317	\$0	62,116	D	
Share Option	\$1.59	05/28/2025		M <sup>(1)</sup>		62,116	(5)	12/15/2025	Class A Ordinary Share	62,116	\$0	0	D	

**Explanation of Responses:**

- This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging between \$27.00 and \$27.03. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging between \$27.00 and \$27.06. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging between \$27.00 and \$27.76. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- The option is fully vested and exercisable.

/s/ Madelyn Zeylikman,  
Attorney-in-Fact

05/28/2025

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**